MedTrace Logo

A Phase I/II Clinical Study of SK&F-105517-D in Japanese Patients With Chronic Heart Failure

NCT00742508 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 41

Last updated 2017-08-02

Study results available
· View outcomes & findings →

Summary

The primary objective of this study is to evaluate the safety and tolerability of SK\&F-105517-D in japanese patients with chronic heart failure.

Conditions

  • Heart Failure, Congestive

Interventions

DRUG

SK&F-105517-D 10 mg capsule

1 capsule once a day

DRUG

Carvedilol-immediate release (IR) 2.5 mg tablet

1 or 2 tablet(s) twice a day

DRUG

SK&F-105517-D 20 mg capsule

1 capsule once a day

DRUG

SK&F-105517-D 40 mg capsule

1 or 2 capsule(s) once a day

DRUG

Carvedilol-IR 10 mg tablet

1 tablet twice a day

Sponsors & Collaborators

Principal Investigators

  • GSK Clinical Trials · GlaxoSmithKline

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
20 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-08-28
Primary Completion
2009-08-21
Completion
2009-08-21

Countries

  • Japan

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00742508 on ClinicalTrials.gov